Ichnos Glenmark Innovation (IGI) has a lot at stake as it readies to present first-time data from the Phase I study of its T cell-engaging trispecific antibody (ISB 2001) at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
IGI, which brings together the innovation capabilities of Ichnos Sciences, a clinical-stage biotech, and parent, Glenmark Pharmaceuticals, believes the trispecific antibody can be “transformational” in the multiple myeloma (MM) space....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?